维普中文期刊产品整合服务
9篇 您的检索式:作者名="PATTISON MA"
    题名 作者 年代 出处 被引量
1Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma显示文摘BACKGROUND Combined hepatocellular and cholangiocarcinoma(HCC/CC)is a rare primary hepatic malignancy which carries a poor prognosis due to its aggressive nature.Few centers have enough cases to draw definitive conclusions and there is limited understanding of prognosis.Given the rarity of HCC/CC,an analysis of large national cancer database was needed to obtain larger number of HCC/CC cases.AIM To identify associated factors for 5-year survival of HCC/CC.METHODS We conducted a retrospective study of The Surveillance,Epidemiology,and End Results(SEER)database obtained from SEER*Stat 8.3.6 software.Previously defined histology code 8180 for the International Classification of Disease for Oncology,3rd edition was used to identify HCC/CC cases from 2004 to 2015.We collected demographics,American Joint Committee on Cancer(AJCC)stage,treatment,tumor size,and survival data.These data were converted to categorical variables.The Shapiro-Wilk normality test was used to assess normal distribution.Mann-Whitney U test was used to compare continuous variables without normal distribution,and t-test was used to compare continuous variables with a normal distribution.The Kaplan-Meier survival curve analyzed 5-year survival.Univariate and multivariate logistic regression model was used to analyze factors associated with 5-year survival.Multivariate Cox proportional hazard regression was done on 5-year survival.We defined P<0.05 was statistically significant.RESULTS We identified 497 patients with the following characteristics:Mean age 62.4 years(SD:11.3),149(30.0%)were female,racial distribution was:276(55.5%)white,53(10.7%)black,84(16.9%)Asian and Pacific Islander(API),77(15.5%)Hispanic,and 7(1.4%)others or unknown.Stage I/II disease occurred in 41.5%and tumor size<50 mm was seen in 35.6%of patients.Twenty-four(4.8%)received locoregional therapy(LRT),119(23.9%)underwent resection,and 50(10.1%)underwent liver transplantation.The overall median survival was 6 mo[Interquartile range(IQR):1-22].After multivariate logistic regression,tumor size<50 mm[Odds ratios(OR):2.415,P=0.05],resection(OR:12.849,P<0.01),and transplant(OR:27.129,P<0.01)showed significance for 5-year survival.Age>60,sex,race,AJCC stages,metastasis,and LRT were not significant.However,API vs white showed significant OR of 2.793(CI:1.120-6.967).Cox proportional hazard regression showed AJCC stages,tumor size<50 mm,LRT,resection,and transplant showed significant hazard ratio.CONCLUSION HCC/CC patients with tumor size<50 mm,resection,and transplant were associated with an increase in 5-year survival.API showed advantageous OR and hazard ratios over white,black.Tomoki Sempokuya Eric A Wien Robert J Pattison Jihyun Ma Linda L Wong 2020World Journal of Hepatology2020,12,11:2
2Three-dimensional, nano-structured PLGA scaffolds for bladder tissue replacement applications 显示文摘Pattison MA Wurster S Webster TJ 2005Biomaterials2005,26,:1
3Accelerated chondrocyte functions on NaOH-treated PLGA scaffolds显示文摘Park GE Pattison MA Park K 0,,16:1
4Three-dimensional,nano-structured PLGA scaffolds for bladder tissue replacement applications显示文摘PATTISON MA WURSTER S WEBSTER TJ 2005Biomaterials2005,26,15:1
5Accelerated chondrocyte functions on NaOH-treated PLGA scaffolds 显示文摘Park GE Pattison MA Park K 2005Biomaterials2005,26,16:1
6Three-dimensional, nanc-structured PLGA scaffolds for bladder tissue replacement applications显示文摘Pattison MA Wurster S Webster TJ 2005Biomaterials2005,26,15:1
7Accelerated chon- drocyte functions on NaOH-treated PLGA scaffolds显示文摘PARK GE PATTISON MA PARK K 2005Biomateri- als2005,26,16:1
8Three-dimensional, nanostructured PLGA scaffolds for bladder tissue replacement applications 显示文摘Pattison MA Wurster S Webster TJ 2005Biomateriais2005,26,:1
9Three-dimensional, nanostructured PLGA scaffolds for bladder tissue replacement applications显示文摘Pattison MA Wurster S Webster TJ 2005Biomaterials2005,26,15:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费